Logo

Omeros Corporation

OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has comple… read more

Healthcare

Biotechnology

16 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$16.59

Price

-3.46%

-$0.59

Market Cap

$1.176b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$121.159m

+22.7%

1y CAGR

-119.6%

3y CAGR

-54.1%

5y CAGR
EPS

-$2.02

+25.2%

1y CAGR

-175.7%

3y CAGR

-153.1%

5y CAGR
Book Value

-$220.478m

$185.706m

Assets

$406.184m

Liabilities

$191.609m

Debt
Debt to Assets

103.2%

-1.7x

Debt to EBITDA
Free Cash Flow

-$105.323m

+29.3%

1y CAGR

-28.5%

3y CAGR

-16.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases